Member Info for bluesky687

ExMS intellectual property

ExMS start reading RNS, they'll give you the answer ... "nanosynth, the AIM quoted company specialising in the synthesis and application of nanoparticles to create new and improve existing products"

Corcel CEO Scott Kaintz - Portfolio Overview & The EV & Energy Market #CRCL

https://www.pscp.tv/w/1mrGmwElgvkxy

so that period will be over tomorrow?

I'm also still very convinced here. Not only because of the masks, but also the technology behind it

good performance today

feels like future is happening now in this exciting / emerging space (microbiome)

You too :D we shall see soon enough

Cvm appears youre too much focused on one single aspect and fail to embed that or see the whole picture and context

Exciting time ahead. Definately!

Keyword to me is "completed" suggesting me that our part is done. Now "only" have to wait I guess

Im truly excited on this one. Fingers crossed it all comes rather sooner than later. Very well positioned company. Perfect times considering gold and copper prices. Happy to be in!

https://www.merck.com/stories/merck-scientists-probe-how-our-bodies-bugs-impact-immunity-and-disease/

busy schedule for 4d, nice

https://www.4dpharmaplc.com/en/newsroom/events

Upcoming events

Society for Immunotherapy of Cancer's 35th Anniversary Annual Meeting (SITC 2020)

9-14 November

Crohn's & Colitis Foundation, IBD Innovate Virtual Conference

17-18 November

Microbiome Movement Drug Development Summit Europe 2021

27-29 January

give it the time required. next readouts / news will surely follow this and or next year. recent interview suggests some exciting opportunities

Consistent with FDA guidance on the clinical evaluation of treatments for IBS, 4D pharma plc ('4D') investigated the effect of Blautix® on both bowel habit and pain as a composite response endpoint. 4D pharma also investigated the treatment across both IBS-C (constipation predominant) and IBS-D (diarrhoea predominant) clinical subtypes, as Blautix® has potential to treat both major subtypes of the disease, unlike other approved products which act only on symptoms associated with either subtype of IBS.

treating the disease to me seems key compared to only treat symptoms? think this makes DDDD / Blautix different?!

"These patients, who account for around 30% of all IBS patients, currently have no approved treatment options. This reflects the broad potential of Blautix as a completely new, safe, flexible therapeutic approach to treating all forms of the condition. The Phase II results provide signals that are highly encouraging and supportive of regulatory engagement around the design of a Phase III pivotal study to provide new therapeutic options to cover the considerable unmet medical need of people suffering from IBS."

Olderandwiser, yet another asumption

you may wish to scroll through my posting history and you will get a flavour

regards,
blue

no matter how you turn it doesnt make sense to talk about a potential poor RNS when company talks about a potential world's first disease modifying therapy for IBS. even if it comes different, it just makes no sense until told otherwise. just my view

The trial has now completed enrolment of approximately 370 patients and 4D pharma expects to announce full topline results in the first few days in Q4. Blautix® has the potential to be the world's first disease modifying therapy for IBS, by treating the underlying microbiome cause of disease. "

Olderandwiser, I shall add "YOUR" talking about a potential poor RNS is nonsense